Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mehta

Showing results (1101-1110 of 1,216) with videos related to

Pageof 122
Sort By:
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 2, 2019
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539C Leland Rogers, Minhee Won, Michael A Vogelbaum, et al.
Neuro-Oncology|November 5, 2025
Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS LymphomaAntonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2025
Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS studyMinesh P Mehta, Vinai Gondi, Manmeet Singh Ahluwalia, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Neurological Research|June 14, 2005
Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?Gelsomina De Stasio, Deepika Rajesh, Patrizia Casalbore, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2025
Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancerRiley E Bergman, Christin I Keeton, Irika R Sinha, et al.
Pageof 122

Showing results (1101-1110 of 1,216) with videos related to

Sort By:
Pageof 122
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 2, 2019
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539C Leland Rogers, Minhee Won, Michael A Vogelbaum, et al.
Neuro-Oncology|November 5, 2025
Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS LymphomaAntonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2025
Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS studyMinesh P Mehta, Vinai Gondi, Manmeet Singh Ahluwalia, et al.
The New England Journal of Medicine|April 7, 2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaJan C Buckner, Edward G Shaw, Stephanie L Pugh, et al.
Neurological Research|June 14, 2005
Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?Gelsomina De Stasio, Deepika Rajesh, Patrizia Casalbore, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2025
Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancerRiley E Bergman, Christin I Keeton, Irika R Sinha, et al.
Pageof 122